Metabolic load during strength training or NMES in individuals with COPD: results from the DICES trial

Maurice JH Sillen, Frits ME Franssen, Anouk W Vaes, Jeannet ML Delbressine, Emiel FM Wouters and Martijn A Spruit

Abstract

Background: Strength training and neuromuscular electrical stimulation (NMES) are effective training modalities for improving muscle function, exercise performance and health status in individuals with COPD. The aim of the present study was to analyze the metabolic load of these training modalities at baseline, half-way, and at the end of an eight-week interdisciplinary pulmonary rehabilitation program in a subgroup of individuals with COPD of the DICES trial.

Methods: Of 24 individuals with COPD (FEV1: 34 ± 2% predicted, men: 58%, age: 66 (61–68) years), peak oxygen uptake (VO2), peak minute ventilation (VE), heart rate, oxygen saturation and symptom scores were assessed during HF-NMES (75 Hz), LF-NMES (15 Hz) and strength training at three moments during their pulmonary rehabilitation program.

Results: Intervention-related peak VO2 did not change over time during HF-NMES, LF-NMES or strength training. Intervention-related peak VE did not change over time during strength training or LF-NMES and increased slightly, but significantly over time during HF-NMES. Peak VO2 and VE were significantly higher during strength training compared to HF-NMES or LF-NMES. Oxygen saturation significantly decreased after the first measurements during HF-NMES and strength training group to baseline, while no significant changes in oxygen saturation were observed during the other measurements. Heart rate significantly increased compared to baseline in all groups at all moments and was significantly higher after strength training compared to HF-NMES or LF-NMES. Median end scores (points) for dyspnea, fatigue and muscle pain ranged from 1 to 3, from 0.5 to 2 and from 0 to 6 after HF-NMES, from 2 to 3, from 2 to 5 and from 0 to 9 after LF-NMES and from 2 to 5, from 1.5 to 4 and from 0 to 28 after strength training respectively.

Conclusions: To conclude, the metabolic load and symptom scores remain acceptable low over time with increasing training loads during HF-NMES, LF-NMES or strength training.

Trial registration: Trial registration: NTR2322

Keywords: Chronic obstructive pulmonary disease, Neuromuscular electrical stimulation, Pulmonary rehabilitation, Strength training

* Correspondence: mauricesillen@ciro-horn.nl

1Department of Research & Education, CIRO+, centre of expertise for chronic organ failure, Horn, the Netherlands

Full list of author information is available at the end of the article

© 2014 Sillen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Individuals with chronic obstructive pulmonary disease (COPD) may suffer from lower-limb muscle weakness and poor exercise capacity, in particular those with severe to very severe dyspnea [1-3]. This is most probably due to reductions in weight-bearing daily physical activities [4]. Therefore, an exercise-based pulmonary rehabilitation program may be beneficial [5]. Severely dyspneic individuals with COPD (i.e., modified MRC dyspnea grade 3 or 4), however, are less likely to complete a pulmonary rehabilitation program [6]. This may be due to exercise-induced dyspnea, particularly during whole-body endurance training [7]. Therefore, strength training [8] or transcutaneous neuromuscular electrical stimulation (NMES) [9,10] may be preferential alternative rehabilitative modalities for severely dyspneic individuals with COPD [11,12]. These interventions are safe and effective in severely dyspneic individuals with COPD and quadriceps muscle weakness at baseline [13]. Indeed, lower-limb muscle function, functional exercise performance, problematic activities of daily life, mood status, and health status improved significantly following eight weeks of strength training, high-frequency (HF, 75 Hertz) NMES, or low-frequency (LF, 15 Hertz) NMES [13].

A major advantage of strength training and NMES is the relatively low metabolic load (e.g., the intervention-related peak oxygen uptake (VO₂) and ventilation (V̇E)), accompanied with relatively low dyspnea symptom scores [14,15]. The metabolic load during multiple successive sessions of strength training has been reported once in 11 individuals with COPD [7]. The leg press strengthening exercise increased significantly during a 12-week pulmonary rehabilitation program (+43% of baseline training load), accompanied by a significant increase in metabolic load over time (+23% of baseline intervention-related peak VO₂; +18% of baseline intervention-related peak V̇E) [7]. The metabolic load during a session of high-frequency (HF) or low-frequency (LF) NMES has only been measured cross-sectionally [14,15]. Whether and to what extent the metabolic load will remain stable over time while the NMES pulse amplitude is expected to increase [16] remains currently unknown in individuals with COPD. Moreover, the actual course of NMES pulse amplitude has never been described in individuals with COPD. This, however, will provide a better insight in the feasibility and efficacy of these types of local muscle training.

The aim of the present study was to analyze the metabolic load of the different local muscle training modalities at baseline, half-way, and at the end of the eight-week program in a subgroup of individuals with COPD who participated in the DICES (Dyspneic Individuals with COPD: Electrical stimulation or Strength training) trial. A priori, we hypothesized that individuals with COPD are able to increase the strength training load or NMES pulse amplitude (irrespective of stimulation frequency), while the metabolic load will remain stable compared to baseline.

Methods

Participants

In the DICES trial, individuals with COPD with mMRC dyspnea grade 3 or 4 [2], and quadriceps weakness [17] were randomly assigned to lower-limb HF-NMES (75 Hertz), lower-limb LF-NMES (15 Hertz), or lower-limb strength training (leg extension strengthening exercise, and leg press strengthening exercise [8,18]). These interventions took place in group sessions, twice per day, 5 times per week for 8 weeks. All sessions were supervised by a physiotherapist. The interdisciplinary treatment was identical for all participants, and treadmill walking or stationary ergometry cycling was not applied during the trial. Symptom scores for dyspnea, fatigue, and muscle pain were assessed before and after each session [19].

The Medical Ethical Committee of the Maastricht University Medical Centre + (MEC 09-3-072) approved this trial, which conformed to the principles outlined in the World Medical Association declaration of Helsinki which was revised in Seoul [20]. Details of the trial were registered at www.trialregister.nl NTR2322) before first subject enrolment. All patients gave written informed consent to participate in the study and a subgroup additionally gave written informed consent to undergo the measurements of the metabolic load. Some of the baseline findings, and the efficacy data of the DICES trial have been published before [21,22].

Interventions

Please, see Additional file 1 for all details.

Outcomes

Outcome assessors were blinded for treatment allocation. The investigators supervising the interventions (MJHS, AWV) were blinded for the initial results, and were not involved in the outcome assessment. Participants were instructed to not divulge their group allocation. Participants, who were randomly assigned to one of the NMES groups, were blinded for the type of stimulation frequency.

Quadriceps muscle function

Quadriceps muscle function (i.e., peak muscle strength and muscle endurance), using a Biodex (Biodex System 4 Pro, Biodex Medical Systems, Inc., New York, USA). Quadriceps peak muscle strength (Newton-meter, Nm) and quadriceps muscle endurance (Joules, J) were measured isokinetically. The participants performed thirty volitional maximal contractions at an angular velocity of 90° per second. See Additional file 1 for all details concerning the interventions.
Functional exercise performance

Functional exercise performance was measured with the 6-min walk test, including a practice walk at initial assessment [23]. The best 6-min walk distance (6MWD) was used for further analyses. The constant work-rate cycling endurance test (CWRT, expressed in seconds) was performed at 75% of the pre-determined peak cycling rate, which has a high reliability in individuals with COPD [24]. Symptom scores for exercise-induced dyspnea and fatigue were assessed before and after these exercise tests.

Metabolic load

Continuous on-line calculations of breath-by-breath oxygen uptake (VO$_2$) and minute ventilation (V$_E$), heart rate and oxygen saturation were obtained using the Oxycon mobile, a portable metabolic system (Carefusion the Netherlands, Houten, the Netherlands). The metabolic load was measured during sessions of HF-NMES, LF-NMES, or strength training in the first week, the fourth week, and in the last week of the trial. This methodology has been used before in individuals with COPD [14,15]. See Additional file 1 for all details concerning the measurement of the metabolic load.

Statistical analysis

Analyses were performed using SPSS for Windows, Version 17.0.1 (SPSS, Inc., Chicago, Il, USA). Descriptive statistics were presented as median and interquartile range unless otherwise stated. Differences within groups were analyzed using Wilcoxon signed rank test. Groups were...
compared using Mann–Whitney U test or Kruskal–Wallis one-way analysis of variance. All tests were two-sided using a significance level of 5%.

Results
Baseline characteristics
Of the 120 individuals who participated in the DICES trial, 61 individuals (51%) were ineligible for the additional metabolic data collection due to the use of long-term oxygen therapy. Moreover, 26 individuals (22%) did not consent to this extra set of tests and 3 individuals (2%) who gave informed consent withdrew before start. At baseline, from 30 individuals (25%) intervention-related peak VO$_2$, VE, heart rate and oxygen saturation were obtained. From 24 individuals the metabolic load was measured during a session of HF-NMES (n = 9), LF-NMES (n = 7), or strength training (n = 8) in the first week, the fourth week, and in the last week of the trial (Figure 1).

The 24 individuals of this pre-specified sub-analysis had severe to very severe COPD, a poor diffusing capacity for carbon monoxide and a poor functional and peak exercise performance (Table 1). Besides age and the relative peak ventilation during the cardiopulmonary

Table 1 General characteristics

|                          | Total group (n = 24) | HF-NMES (n = 9) | LF-NMES (n = 7) | Strength training (n = 8) | P-value |
|--------------------------|---------------------|-----------------|-----------------|--------------------------|---------|
| Sex (M/F)                | 14/10               | 6/3             | 4/173           | 4/4                      | 0.791   |
| Age (years)              | 66 (61–68)          | 64 (59–67)      | 62 (59–67)      | 71 (66–77)               | 0.012   |
| Pulmonary function       |                     |                 |                 |                          |         |
| FEV$_1$ (liters)         | 0.98 (0.78–1.05)    | 1.01 (0.84–1.19)| 0.74 (0.60–0.84)| 1.00 (0.96–1.10)         | 0.010   |
| FEV$_1$ (% predicted)    | 35 (29–51)          | 34 (23–51)      | 30 (20–38)      | 46 (43–60)               | 0.064   |
| FEV$_1$/VC max (%)       | 32 (24–43)          | 31 (24–41)      | 25 (24–29)      | 42 (33–52)               | 0.057   |
| DLCO (%)                 | 42 (36–55)          | 41 (31–55)      | 42 (34–61)      | 46 (40–56)               | 0.802   |
| RV (%)                   | 177 (136–235)       | 190 (137–243)   | 208 (172–260)   | 146 (128–178)            | 0.081   |
| Arterial blood gases     |                     |                 |                 |                          |         |
| PaO$_2$ (kPa)            | 9.8 (8.8–10.8)      | 9.0 (8.5–10.9)  | 9.6 (8.5–9.9)   | 10.3 (9.4–11.2)           | 0.284   |
| PaCO$_2$ (kPa)           | 4.9 (4.7–5.5)       | 5.4 (4.8–5.7)   | 5.0 (4.7–5.6)   | 4.8 (4.6–5.1)            | 0.159   |
| SaO$_2$ (%)              | 96 (95–97)          | 95 (95–97)      | 95 (94–97)      | 97 (96–98)               | 0.166   |
| GOLD classification (I/II/III/IV) | 0/7/10/7       | 0/3/3/3         | 0/0/4/3         | 0/4/3/1                  | 0.025   |
| GOLD classification (new) (A/B/C/D) | 0/3/0/21       | 0/2/0/7         | 0/0/0/7         | 0/1/0/7                  | 0.427   |
| BMI (kg/m$^2$)           | 25.4 (22.2–29.8)    | 25.4 (21.9–26.9)| 24.6 (23.5–30.3)| 26.9 (21.5–31.1)         | 0.834   |
| FFMI (kg/m$^2$)          | 17.0 (15.8–18.5)    | 16.9 (15.7–17.5)| 16.5 (15.7–18.8)| 17.4 (15.8–19.1)         | 0.680   |
| Cardiopulmonary exercise test |                   |                 |                 |                          |         |
| Peak load (watts)        | 47 (35–57)          | 51 (35–57)      | 46 (41–62)      | 44 (30–58)               | 0.867   |
| Peak load (% predicted)  | 33 (23–47)          | 26 (23–39)      | 38 (22–81)      | 39 (23–63)               | 0.481   |
| Peak VO$_2$ (ml/min)     | 841 (710–987)       | 751 (697–919)   | 817 (734–1087)  | 904 (699–1076)           | 0.473   |
| Peak VO$_2$ (% predicted) | 48 (33–73)          | 31 (27–64)      | 53 (40–90)      | 52 (40–115)              | 0.142   |
| Peak VE (liters)         | 33 (29–39)          | 38 (28–41)      | 32 (25–35)      | 35 (29–44)               | 0.553   |
| Peak VE (% MVV)          | 89 (78–107)         | 84 (72–98)      | 103 (95–119)    | 81 (68–101)              | 0.040   |
| Peak HR (bpm)            | 104 (98–124)        | 103 (98–122)    | 126 (104–131)   | 102 (90–109)             | 0.080   |
| Peak HR (% predicted)    | 71 (64–75)          | 66 (64–73)      | 75 (68–83)      | 70 (63–72)               | 0.186   |
| Dyspnea, end (points)    | 7 (5–8)             | 7 (5–7)         | 7 (7–9)         | 8 (5–9)                  | 0.526   |
| Fatigue, end (points)    | 5 (3–7)             | 5 (3.5–7.5)     | 5 (3–7)         | 4 (3–7)                  | 0.861   |
| Saturation, end (%)      | 91 (89–95)          | 93 (91–98)      | 90 (89–91)      | 94 (89–96)               | 0.132   |

Values expressed as median (interquartile range) or numbers. Data are compared between HF-NMES, LF-NMES and strength training. Abbreviations: HF-NMES = High-frequency transcutaneous neuromuscular electrical stimulation; LF-NMES = Low-frequency transcutaneous neuromuscular electrical stimulation; M = males; F = females; FEV$_1$ = forced expiratory volume in one second; VC = maximum vital capacity; DL$_{CO}$ = diffusion capacity of the lung for carbon monoxide; RV = residual volume; PaO$_2$ = resting arterial oxygen tension; PaCO$_2$ = resting arterial carbon dioxide tension; SaO$_2$ = resting arterial oxygen tension; kPa = kilopascal; LTOT = long-term oxygen therapy; GOLD = Global Initiative on Obstructive Lung Diseases; BMI = body mass index; FFMI = fat free mass index; kg/m$^2$ = kilogram per square meter; VO$_2$ = oxygen uptake; tSaO$_2$ = transcutaneous oxygen saturation; ml/min = milliliters per minute; % MVV = percentage maximal voluntary ventilation; bpm = beats per minute.
exercise test, baseline characteristics did not significantly differ between intervention groups (Table 1). Mean FEV₁ (34 ± 2% versus 31 ± 1% pred), PaCO₂ (5.2 ± 0.1 kPa versus 5.8 ± 0.1 kPa), fat-free mass index (17.2 ± 0.4 kg/m² versus 16.3 ± 0.2 kg/m²) and total work (1389 ± 95 J versus 1122 ± 49 J) were significantly higher in the metabolic load group compared to the remaining group, other baseline characteristics (age, DLco, residual volume, PaO₂, SO₂, peak and functional exercise performance, body mass index, peak torque, HADS anxiety and depression and health status) were not significantly different between both groups (Additional file 1: Table S1).

Efficacy of interventions

**Quadriceps muscle strength**

Isokinetic quadriceps peak torque increased significantly following HF-NMES (12.6 Nm (3.0-17.5 Nm); p = 0.021), but not following LF-NMES (4.2 Nm (−5.2-5 Nm); p = 0.866) or strength training (5.7 Nm (−9-22 Nm); p = 0.263) (Figure 2). There were no significant between-group differences in changes.

**Quadriceps muscle endurance**

Isokinetic total work increased significantly following HF-NMES (292 J (156–501 J); p < 0.01), but not following LF-NMES (12 J (−73-178 J); p = 0.499) or strength training (157 J (−185-456 J); p = 0.263) (Figure 2). The improvement following HF-NMES was significantly higher compared to LF-NMES (p = 0.005) (Figure 2).

**Six-minute walk distance**

6MWD improved significantly following HF-NMES (75 m (29–138 m); p = 0.008) or strength training (57 m (32–85 m); p = 0.034), but not following LF-NMES (27 m (−34-65 m); p = 0.310). There were no significant differences in changes between groups.

**Constant work-rate test**

Endurance time during the constant work-rate cycling test improved significantly following HF-NMES (92 s (49–275 s); p = 0.066), LF-NMES (83 s (−7-223 s); p = 0.091) or strength training (37 s (1–98 s); p = 0.043). There were no significant differences in changes between groups.

**Course of HF-NMES, LF-NMES or strength training**

In the HF-NMES group, pulse amplitude ranged from 12 to 40 mA in week one to 34 to 71 mA in week eight (p = 0.008); and in the LF-NMES group from 25 to 50 mA to 35 to 98 mA (p = 0.063, Figure 3). Median end dyspnea scores, end fatigue scores and end muscle pain scores ranged from 1 to 3 points, from 0.5 to 2 points and from 0 to 6 points in the HF-NMES group and from 2 to 3 points, from 2 to 5 points and from 0 to 9 points in the LF-NMES group respectively. The load during leg extension strengthening exercise ranged from 2.5 to

![Figure 2](http://www.biomedcentral.com/1471-2466/14/146) Individual changes in quadriceps peak torque and total work from baseline to end. Abbreviations: HF-NMES=high-frequency transcutaneous neuromuscular electrical stimulation; LF-NMES=low-frequency transcutaneous neuromuscular electrical stimulation (quadriceps peak torque: A, B and C; quadriceps muscle endurance: D, E and F). The bold line represents the median values.
20 kg in week one to 12.5 to 27.5 kg in week eight; and from 5 to 70 kg to 35 to 90 kg for the leg press strengthening exercise (both \( p < 0.02 \), Figure 3). In addition, median end dyspnea scores, end fatigue scores and end muscle pain scores ranged from 2 to 5 points, from 1.5 to 4 points and from 0 to 28 points in the strength training group.

**Metabolic load during HF-NMES, LF-NMES or strength training**

Intervention-related peak VO\(_2\) did not change over time all three interventions (Figure 4A, Table 2). Intervention-related peak VE did not change over time in the strength training or LF-NMES group (\( p > 0.171 \)). In the HF-NMES group, the intervention-related VE increased slightly, but significantly over time (\( p = 0.012 \), Figure 4B). At all measurement points, intervention-related peak VO\(_2\) and VE were significantly higher during strength training sessions compared to the HF-NMES or LF-NMES sessions (all \( p < 0.05 \)). There were no differences between HF-NMES and LF-NMES (\( p > 0.28 \)). Oxygen saturation (lowest values) was significant lower at the end of the fist measurements in the HF-NMES group and the strength training group compared with baseline (both \( p < 0.03 \)), during the other measurements no significant changes in oxygen saturation were observed (all \( p > 0.05 \)) (Table 3). There were no significant between-group differences in changes in oxygen saturation (all \( p > 0.05 \)). Heart rate was significantly higher at the end compared to baseline in all groups in all

|                  | HF-NMES | LF-NMES | Strength training |
|------------------|---------|---------|-------------------|
| \( n = 9 \)      |         |         |                   |
| VO\(_2\) ml/min  | 424 (312–438) | 369 (323–512) | 630 (593–759) |
| VE L/min         | 19 (15–22)    | 20 (15–24)   | 26 (23–33)       |
| VO\(_2\) ml/min  | 387 (345–418) | 454 (335–530) | 659 (576–754) |
| VE L/min         | 17 (16–20)    | 21 (16–25)   | 30 (25–33)       |
| VO\(_2\) ml/min  | 438 (366–619) | 447 (329–518) | 725 (603–861) |
| VE L/min         | 21 (17–25)    | 20 (15–24)   | 30 (27–33)       |

Values expressed as median (interquartile range). Abbreviations: HF-NMES = high-frequency transcutaneous neuromuscular electrical stimulation; LF-NMES = low-frequency transcutaneous neuromuscular electrical stimulation; VO\(_2\) = oxygen uptake; VE = ventilation; ml/min = milliliters per minute; L/min = liters per minute.
measurements (p < 0.05) (Table 3). During all measurements, changes in heart rate were significantly higher after strength training compared to HF-NMES or LF-NMES (p < 0.04).

**Discussion**

This is the first study to investigate the metabolic load of various local muscle training modalities in severely dyspneic COPD patients with quadriceps muscle weakness during the course of an inpatient pulmonary rehabilitation program. It showed that the metabolic load measured during successive sessions of strength training, HF-NMES, or LF-NMES remained generally stable, while the NMES pulse amplitude or the strength training load increased significantly during the eight-week intervention period.

The median oxygen uptake during the baseline session of HF-NMES, LF-NMES or strength training ranged between 30 and 99% of the peak aerobic capacity measured during the cardiopulmonary exercise test, and was comparable with previous studies [7,14,15]. The median oxygen uptake was 99% of the peak aerobic capacity in one subject who was characterized with very severe COPD (FEV₁: 17% pred) and a very decreased exercise capacity (peak load: 20% pred; VO₂ peak: 688 ml/min (26% pred)). At all measurement points, intervention-related peak VO₂ and V̇E were significantly lower during NMES compared with voluntary exercise [25]. Besides the study design and subjects, an important difference with the present study is the training load [25]. Theurel and colleagues used an average training load in strength training of 46% of the maximal voluntary contraction instead of 60-70% of the one-repetition maximum which is used in our study and what is recommended by the American College of Sports Medicine [8].

The present study shows no changes over time in the metabolic load which is not in line with the study of Probst and colleagues [7]. Probst and colleagues showed a significant increase in oxygen uptake and ventilation during a 12 wk program of leg press exercises [7]. This could be attributable to a greater increase in the training load. However, the change in training load of leg press exercises was comparable to the present study.

The median increase in pulse amplitude during the study was 24 mA in HF-NMES and 37 mA in LF-NMES. The course in pulse amplitude is comparable with previous studies in severely disabled patients with COPD which respond to NMES [16,26]. The low metabolic load accompanied with acceptable low dyspnea and fatigue scores probably explains the applicability of these interventions in severely disabled and dyspneic patients, even during acute COPD exacerbations [26-28]. This is also probably the reason that NMES can easily be applied in bed-bound individuals with chronic hypercapnic respiratory failure due to COPD who are receiving mechanical ventilation [29] or critically ill patients in the intensive care unit [30].

Because of the constant metabolic load in combination with stable symptom scores over time, it seems reasonable to hypothesize that the improvements in muscle function are at least partially due to intramuscular changes. Previously, it has been shown that type I and IIa fibers increased following LF-NMES [31,32] or HF-NMES [33,34]. Strength training generally results in  

### Table 3 Oxygen saturation and peak heart rate during HF-NMES, LF-NMES or strength training

|                     | HF-NMES | LF-NMES | Strength training |
|---------------------|---------|---------|------------------|
|                     | n = 9   | n = 8   | n = 7            |
| **First measurement** |         |         |                  |
| SpO₂ %              | 96 (92–97) | 89 (86–96) | 95 (89–95) |
| Heart rate bpm      | 83 (77–87) | 95 (80–106) | 66 (60–91) |
| **Second measurement** |         |         |                  |
| SpO₂ %              | 93 (88–97) | 94 (92–98) | 92 (90–94) |
| Heart rate bpm      | 83 (78–89) | 87 (85–97) | 74 (58–89) |
| **Third measurement** |         |         |                  |
| SpO₂ %              | 93 (89–98) | 87 (85–96) | 95 (91–96) |
| Heart rate bpm      | 82 (73–90) | 84 (77–98) | 76 (62–93) |

Values expressed as median (interquartile range).
Abbreviations: HF-NMES = high-frequency transcutaneous neuromuscular electrical stimulation; LF-NMES = low-frequency transcutaneous neuromuscular electrical stimulation; SpO₂ = oxygen saturation; bpm = beats per minute.
increased levels of glycolytic enzymes [35] and an increase in percentage and size of type II fibers [36-39].

Obviously, this study has some limitations. First, the inclusion criteria of the DICES trial limits the external validity of the present findings. Only COPD patients with an mMRC score of 3 and 4 in combination with muscle weakness were included. Secondly, the small sample size and selected patient characteristics for participation in the measurements with the Oxygenon mobile may be an important reason for detecting no significant improvements in peak muscle strength in the strength training group and quadriceps muscle endurance in the LF-NMES group and the strength training group. Only patients without long-term oxygen therapy (LTOT) were eligible to participate due to the methodology used [7], although LTOT patients are also likely to have benefit from these interventions. However, the equipment (Oxygenon mobile, a portable metabolic system) is not able to measure oxygen uptake (VO2) while breathing inspiratory O2 fractions [7]. In the DICES trial 51% of the patients used LTOT [40]. It is unclear if the metabolic load might be different in LTOT patients. Moreover, the small sample size and the exclusion of LTOT patients may limit the external validity and broad applicability of these findings.

Conclusion
To conclude, the metabolic load and symptom scores for dyspnea, fatigue and muscle pain remain acceptable low over time with increasing training loads during HF-NMES, LF-NMES or strength training. For this reason, these interventions are recommended in severely dyspneic patients with COPD for improving their muscle function and exercise performance.

Additional file

Additional file 1: Online Supplement.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Study concept and design: MJHS, EFMW and MAS; acquisition of data: MJHS, JMLD, AW; analysis and interpretation of data: MJHS, FMEF and MAS; drafting the article: MJHS, FMEF and MAS; revising it critically for important intellectual content: all authors; final approval of the version to be published: all authors. MJHS had full access to all study data and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements
The present authors are grateful to the patients who volunteered in the DICES trial. The authors also thank Martijn Cuipers and Martyna Renckers for their valuable help. This research was supported by grants from the Lung Foundation, Leusden, the Netherlands, Grant 34059024 and the Weijerhorst Foundation, Maastricht, the Netherlands.

Author details
1Department of Research & Education, CIRO+, centre of expertise for chronic organ failure, Hormeerheide 1, Horn, the Netherlands. 2Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands.

Received: 24 April 2014 Accepted: 26 August 2014 Published: 2 September 2014

References
1. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, Gosker HR, Schols AM, Moxham J, Polkey MI, Wouters EF: The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010, 36(1):81-88.
2. Spruit MA, Penningts HJ, Janssen PP, Does JD, Sceyren S, Akkermans MA, Mostert R, Wouters EF: Extra-pulmonary features in COPD patients entering rehabilitation after stratification for MRC dyspnea grade. Respir Med 2007, 101(12):2454–2463.
3. Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, Celli BR, Tal-Singer R, Wouters EF: Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med 2010, 104(6):849–857.
4. Waschki B, Spruit MA, Watz H, Albert PS, Shrikirshna D, Groenen M, Smith C, Man WD, Tal-Singer R, Edwards LD, Calverley PM, Magnusen H, Polkey MI: Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012, 106(5):522–530.
5. Spruit MA, Singh SJ, Ganey C, Zuwallack R, Nici L, Rochester C, Hill K, Holland AE, Layeau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Malais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF, et al: An official american thoracic society/european respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013, 188(8):e1–e64.
6. Hogg L, Garrod R, Thornton H, McDonnell L, Bellas H, White P: Effectiveness, attendance, and completion of an integrated, system-wide pulmonary rehabilitation service for COPD: prospective observational study. COPD 2012, 9(5):546–554.
7. Probst VS, Troosters T, Pitta F, Decramer M, Gosselink R: Cardiopulmonary stress during exercise training in patients with COPD. Eur Respir J 2006, 27(6):1110–1118.
8. American College of Sports Medicine position stand: Progression models in resistance training for healthy adults. Med Sci Sports Exerc 2009, 41(3):687–708.
9. Maffulli N: Physiological and methodological considerations for the use of neuromuscular electrical stimulation. Eur J Appl Physiol 2010, 110(2):223–234.
10. Vanderhommen M, Duchateau J: Electrical stimulation as a modality to improve performance of the neuromuscular system. Exerc Sport Sci Rev 2007, 35(4):180–185.
11. Spruit MA, Wouters EF: New modalities of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Sports Med 2007, 37(6):501–518.
12. Sillen MJ, Speksnijder CM, Eterna RM, Janssen PP, Waggers SS, Wouters EF, Usko-Lener NH, Spruit MA: Effects of neuromuscular electrical stimulation of muscles of embulation in patients with chronic heart failure or COPD: a systematic review of the English-language literature. Chest 2009, 136(1):64–61.
13. Sillen MJ, Franssen FM, Delbressine JN, Vlaes AW, Wouters EF, Spruit MA: Efficacy of lower-limb muscle training modalities in severely dyspneic individuals with COPD and quadriceps muscle weakness: results from the DICES trial. Thorax 2014, 69(5):525–531.
14. Sillen MJ, Janssen PP, Akkermans MA, Wouters EF, Spruit MA: The metabolic response during resistance training and neuromuscular electrical stimulation (NMES) in patients with COPD, a pilot study. Respir Med 2008, 102(8):796–799.
15. Sillen MJ, Wouters EF, Franssen FM, Meijer K, Stakenborg KH, Spruit MA: Oxygen uptake, ventilation, and symptoms during low-frequency versus high-frequency NMES in COPD: a pilot study. Lung 2011, 189(1):21–26.
16. Woodziev I, Debagire R, Gagnon P, Mainong V, Savy D, Dubé A, Pare ME, Belanger M, Maltais F: Functional and muscular effects of neuromuscular
electrical stimulation in patients with severe COPD: a randomized clinical trial. Chest 2012, 141(3):716–725.

17. Borges O: Isometric and isokinetic knee extension and flexion torque in men and women aged 20–70. Scand J Rehabil Med 1989, 21(1):45–53.

18. Spruit MA, Gosselink R, Troosters T, De Paepe K, Decramer M: Resistance versus endurance training in patients with COPD and peripheral muscle weakness. Eur Respir J 2002, 19(6):1072–1078.

19. Revill SI, Robinson JO, Rosen M, Hogg MI: The reliability of a linear analogue for evaluating pain. Anesthesia 1976, 31(9):1191–1198.

20. Wegmann H: The “new” Declaration of Helsinki. J Int Biotechnol Law 2009, 6(4):173–176.

21. Sillen MJ, Franssen FM, Delbressine JM, Uszko-Lencer NH, Vanfleteren LE, Ruten EF, Wouters EF, Spruit MA: Heterogeneity in clinical characteristics and co-morbidities in dyspneic individuals with COPD GOLD D: findings of the DICES trial. Respir Med 2013, 107(8):1186–1194.

22. Sillen MJ, Franssen FM, Delbressine JM, Vaes AW, Wouters EF, Spruit MA: Efficacy of lower-limb muscle training modalities in severely dyspneic individuals with chronic obstructive pulmonary disease and quadriceps muscle weakness: results from the DICES trial. Thorax 2013, in press.

23. Hernandez NA, Wouters EF, Meijer K, Annegem J, Pitta F, Spruit MA: Reproducibility of 6-minute walking test in patients with COPD. Eur Respir J 2011, 38(2):261–267.

24. Hul van ’t A, Gosselink R, Kwakkel G:Constant-load cycle endurance performance: test-retest reliability and validity in patients with COPD. J Cardiopulm Rehabil 2003, 23(2):143–150.

25. Theurel J, Lepers R, Pardon L, Maffiuletti NA: Differences in cardiorespiratory and neuromuscular responses between voluntary and stimulated contractions of the quadriceps femoris muscle. Respir Physiol Neurobiol 2007, 157(2–3):341–347.

26. Giavedoni S, Deans A, McCaughpey P, Drost E, Hul van’t A, Gosselink R, Kwakkel G: Constant-load cycle endurance performance: test-retest reliability and validity in patients with COPD. J Cardiopulm Rehabil 2003, 23(2):143–150.

27. Abdellaoui A, Prefaut C, Gouzi F, Couillard A, Coisy-Quivy M, Hugon G, Maloini L, Lafontaine T, Jonquet O, Laoudj-Chenivesse D, Hayot M: Skeletal muscle effects of electrostimulation after COPD exacerbation: a pilot study. Eur Respir J 2011, 38(4):781–788.

28. Troosters T, Probst VS, Crul T, Pitta F, Gayan-Ramirez G, Decramer M, Gosselink R: Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181(10):1072–1077.

29. Zanotti E, Felicetti G, Maini M, Fracchia C: Effects of transcutaneous short-term electrical stimulation on M. vastus lateralis characteristics of healthy young men. Pflugers Arch 2002, 443(5–6):866–874.

30. Tesch PA, Thorsson A, Essen-Gustavsson B: Enzyme activities of FT and ST muscle fibers in heavy-resistance trained athletes. J Appl Physiol 1989, 67(1):83–87.

31. Nuhr M, Crevenna R, Gohlsch B, Bittner C, Pleiner J, Wiesinger G, Theriault R, Boulay MR, Theriault G, Simoneau JA: Neuromuscular electrical stimulation training in bed-bound patients with COPD receiving mechanical ventilation: effect of electrical stimulation. Chest 2003, 124(1):292–296.

32. Sillen MJ, Franssen FM, Delbressine JM, Vaes AW, Wouters EF, Spruit MA: Efficacy of lower-limb muscle training modalities in severely dyspneic individuals with COPD: results from the DICES trial. Thorax 2013, in press.

33. Gondin J, Brocca L, Bellingzona E, D’Antona G, Maffiuletti NA, Miotti D, Pellegrino MA, Bottinelli R: Neuromuscular electrical stimulation training induces atypical adaptations of the human skeletal muscle phenotype: a functional and proteomic analysis. J Appl Physiol 2011, 110(2):433–450.

34. Perez M, Lucia A, Rivero JL, Serrano AL, Calbet JA, Delgado MA, Chicharro JL: Effects of transcutaneous short-term electrical stimulation on M. vastus lateralis characteristics of healthy young men. Pflugers Arch 2002, 443(5–6):866–874.

35. Tesch PA, Thorsson A, Essen-Gustavsson B: Enzyme activities of FT and ST muscle fibers in heavy-resistance trained athletes. J Appl Physiol 1989, 67(1):83–87.

36. Sillen MJ, Franssen FM, Delbressine JM, Vaes AW, Wouters EF, Spruit MA: Efficacy of lower-limb muscle training modalities in severely dyspneic individuals with COPD: results from the DICES trial. BMC Pulmonary Medicine 2014 14:146.